Research programme: type 2 diverse natural killer T cell agonists - GRI BIO
Alternative Names: GRI-NKT; Type 2 diverse NKT (dNKT) agonistLatest Information Update: 04 Aug 2025
At a glance
- Originator GRI Bio
- Class
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 29 Jul 2025 Preclinical trials in Unspecified in USA (unspecified route) (GRI BIO pipeline, July 2025)